Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lidocaine hydrochloride monohydrate 21.3 mg/ml equivalent to 20 mg lignocaine hydrochloride anhydrous - oral solution - 2% w/v - active: lidocaine hydrochloride monohydrate 21.3 mg/ml equivalent to 20 mg lignocaine hydrochloride anhydrous excipient: carmellose sodium cherry extract fache 5913g methyl hydroxybenzoate propyl hydroxybenzoate purified water saccharin sodium sodium hydroxide - xylocaine viscous solution is indicated for the relief of pain and discomfort associated with: · irritated or inflamed mucous membranes of the mouth, pharynx and upper gastrointestinal tract, e.g. post-tonsillectomy sore throat, dumping syndrome · introduction of instruments and catheters into the respiratory and gastrointestinal tract.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - leflunomide 10mg - film coated tablet - 10 mg - active: leflunomide 10mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - leflunomide 20mg - film coated tablet - 20 mg - active: leflunomide 20mg excipient: colloidal silicon dioxide crospovidone hypromellose iron oxide yellow lactose monohydrate macrogol 8000 magnesium stearate maize starch povidone purified talc titanium dioxide - arava is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. arava is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.021%{relative} (micronized); triamcinolone acetonide 0.021%{relative} (micronized) - topical cream - 0.02% w/w - active: triamcinolone acetonide 0.021%{relative} (micronized) excipient: benzyl alcohol emulsifying wax glycerol isopropyl palmitate lactic acid purified water sorbitol active: triamcinolone acetonide 0.021%{relative} (micronized) excipient: benzyl alcohol emulsifying wax glycerol isopropyl palmitate lactic acid purified water sorbitol - in the treatment of the following dermatoses; atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, eczematised psoriasis, neurodermatitis.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.05%{relative};  ;   - topical cream - 0.05 % - active: triamcinolone acetonide 0.05%{relative}     excipient: benzyl alcohol emulsifying wax glycerol isopropyl palmitate lactic acid purified water sodium hydroxide sorbitol as 70% solution

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.02% - topical ointment - 0.02% w/w - active: triamcinolone acetonide 0.02% excipient: white soft paraffin - in the treatment of the following dermatoses; atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, eczematised psoriasis, neurodermatitis.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - triamcinolone acetonide 0.05%;  ;   - topical ointment - 0.05 % - active: triamcinolone acetonide 0.05%     excipient: white soft paraffin

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline 1mg;   - solution for injection - 1mg/10ml - active: adrenaline 1mg   excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite tartaric acid water for injection - adrenaline 1:10,000. an adjunct in the management of cardiac arrest.

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline 1 mg/ml;   - solution for injection - 1 mg/ml - active: adrenaline 1 mg/ml   excipient: sodium chloride sodium metabisulfite tartaric acid water for injection - latest regulatory activity

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ciprofloxacin 2 mg/ml;   - solution for injection - 2 mg/ml - active: ciprofloxacin 2 mg/ml   excipient: glucose monohydrate lactic acid water for injection - hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms) - skin and skin structure - septicaemia - bone and joint - urinary tract ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.